TOP TEN perturbations for 39576_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39576_at
Selected probe(set): 210304_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39576_at (210304_at) across 6674 perturbations tested by GENEVESTIGATOR:
HIV-associated neurocognitive disorder study 7 (normal) / HIV-associated neurocognitive disorder study 6 (normal)
Relative Expression (log2-ratio):-1.7735825Number of Samples:2 / 2
| Experimental | HIV-associated neurocognitive disorder study 7 (normal) |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART). | |
| Control | HIV-associated neurocognitive disorder study 6 (normal) |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients did not receive any antiretroviral therapy (ART). |
DLBCL study 1 (activated B-cell like; naïve-like) / DLBCL study 1 (activated B-cell like; centrocyte-like)
Relative Expression (log2-ratio):1.3722525Number of Samples:2 / 8
| Experimental | DLBCL study 1 (activated B-cell like; naïve-like) |
| Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS). | |
| Control | DLBCL study 1 (activated B-cell like; centrocyte-like) |
| Centrocyte B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS). |
ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Relative Expression (log2-ratio):1.3531027Number of Samples:13 / 2
| Experimental | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). |
DLBCL study 1 (activated B-cell like; unclassified) / DLBCL study 1 (activated B-cell like; naïve-like)
Relative Expression (log2-ratio):-1.2889462Number of Samples:11 / 2
| Experimental | DLBCL study 1 (activated B-cell like; unclassified) |
| Unclassified B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS). | |
| Control | DLBCL study 1 (activated B-cell like; naïve-like) |
| Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS). |
ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):1.2805614Number of Samples:13 / 2
| Experimental | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
TC-71 / TC-32
Relative Expression (log2-ratio):1.2635031Number of Samples:6 / 6
| Experimental | TC-71 |
| Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code: | |
| Control | TC-32 |
| Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code: |
ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):1.2514648Number of Samples:13 / 2
| Experimental | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
DLBCL study 1 (activated B-cell like; naïve-like) / DLBCL study 1 (activated B-cell like; memory-like)
Relative Expression (log2-ratio):1.2495823Number of Samples:2 / 3
| Experimental | DLBCL study 1 (activated B-cell like; naïve-like) |
| Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS). | |
| Control | DLBCL study 1 (activated B-cell like; memory-like) |
| Memory B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS). |
mechanical injury study 1 (non-smoker; 14d) / mechanical injury study 1 (non-smoker; 7d)
Relative Expression (log2-ratio):1.2251282Number of Samples:2 / 3
| Experimental | mechanical injury study 1 (non-smoker; 14d) |
| Bronchial epithelial cells of the large (2nd - 3rd order) bronchi from healthy non-smokers were sampled 14 days after mechanical injury by airway brushing during bronchoscopy. Disposable brushes (2.0 mm) were used to injure airway epithelial cells by gently gliding the brush back and forth 10 times in different locations in the same general area. Individuals were determined to be phenotypically normal based on standard history, physical exam, complete blood count, coagulation studies, liver function tests, urine studies, chest X-ray, EKG, and pulmonary function tests. | |
| Control | mechanical injury study 1 (non-smoker; 7d) |
| Bronchial epithelial cells of the large (2nd - 3rd order) bronchi from healthy non-smokers were sampled 7 days after mechanical injury by airway brushing during bronchoscopy. Disposable brushes (2.0 mm) were used to injure airway epithelial cells by gently gliding the brush back and forth 10 times in different locations in the same general area. Individuals were determined to be phenotypically normal based on standard history, physical exam, complete blood count, coagulation studies, liver function tests, urine studies, chest X-ray, EKG, and pulmonary function tests. |
glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):-1.2152276Number of Samples:3 / 3
| Experimental | glioma study 17 (astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |